{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Caffeine+%28200+mg%29", "query": { "intervention": "Caffeine (200 mg)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Caffeine+%28200+mg%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T17:04:14.533Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02411318", "title": "Influence of Lifestyle Factors on Neutrophil Migration Pilot Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neutrophil Chemotactic Response" ], "interventions": [ { "name": "Exercise", "type": "BEHAVIORAL" }, { "name": "ProLab 200mg caffeine capsule", "type": "DRUG" }, { "name": "Ethanol ingestion", "type": "OTHER" }, { "name": "Glucose Tolerance Drink", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG", "OTHER" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "21 Years to 60 Years" }, "enrollment_count": 47, "start_date": "2014-09-25", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-09-25T17:04:14.533Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02411318" }, { "nct_id": "NCT05657613", "title": "Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interactions" ], "interventions": [ { "name": "CYP450 Cocktail and Transporter Substrates with Pacritinib", "type": "DRUG" }, { "name": "Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib", "type": "DRUG" }, { "name": "Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 60, "start_date": "2023-01-03", "completion_date": "2023-06-08", "has_results": false, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-09-25T17:04:14.533Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05657613" }, { "nct_id": "NCT00223691", "title": "Treatment of Orthostatic Hypotension in Autonomic Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autonomic Failure", "Orthostatic Hypotension" ], "interventions": [ { "name": "Atomoxetine", "type": "DRUG" }, { "name": "Acarbose", "type": "DRUG" }, { "name": "Pyridostigmine Bromide", "type": "DRUG" }, { "name": "Yohimbine", "type": "DRUG" }, { "name": "Midodrine HCl", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Modafinil", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "water intake", "type": "OTHER" }, { "name": "Diphenhydramine Hydrochloride", "type": "DRUG" }, { "name": "Ranitidine HCL", "type": "DRUG" }, { "name": "Tranylcypromine", "type": "DRUG" }, { "name": "Ergotamine/ Caffeine", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Pseudoephedrine", "type": "DRUG" }, { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Oxymetazoline 0.05% nasal solution", "type": "DRUG" }, { "name": "Bovril", "type": "DIETARY_SUPPLEMENT" }, { "name": "Acetazolamide", "type": "DRUG" }, { "name": "Rivastigmine tartrate", "type": "DRUG" }, { "name": "Carbidopa/levodopa", "type": "DRUG" }, { "name": "Inflatable abdominal binder", "type": "DEVICE" }, { "name": "inflatable abdominal binder (sham)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DIETARY_SUPPLEMENT", "DEVICE" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 389, "start_date": "2002-03", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-01-18", "last_synced_at": "2026-09-25T17:04:14.533Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00223691" }, { "nct_id": "NCT02685462", "title": "Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tobira Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2016-01-31", "completion_date": "2016-02-23", "has_results": false, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-09-25T17:04:14.533Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02685462" }, { "nct_id": "NCT06763172", "title": "Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthy", "Caffeine", "Adenosine", "Dopamine D2/3 Receptor Availability" ], "interventions": [ { "name": "Caffeine (200 mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hsiao-Ying Wey", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 12, "start_date": "2023-05-17", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-01-09", "last_synced_at": "2026-09-25T17:04:14.533Z", "location_count": 1, "location_summary": "Charlestown, Massachusetts", "locations": [ { "city": "Charlestown", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06763172" }, { "nct_id": "NCT05811923", "title": "Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metabolic Syndrome", "Caffeine" ], "interventions": [ { "name": "Venous Blood Collection", "type": "OTHER" }, { "name": "Resting Metabolic Rate Determination", "type": "OTHER" }, { "name": "Mood State", "type": "OTHER" }, { "name": "Visual Analog Scales", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Lindenwood University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 20, "start_date": "2021-12-12", "completion_date": "2022-10-12", "has_results": false, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-09-25T17:04:14.533Z", "location_count": 1, "location_summary": "Saint Charles, Missouri", "locations": [ { "city": "Saint Charles", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05811923" }, { "nct_id": "NCT04425902", "title": "Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254 200 mg", "type": "DRUG" }, { "name": "Caffeine 200 mg", "type": "DRUG" }, { "name": "Metoprolol 100 mg", "type": "DRUG" }, { "name": "Montelukast 10 mg", "type": "DRUG" }, { "name": "Flurbiprofen 100 mg", "type": "DRUG" }, { "name": "Omeprazole 40 mg", "type": "DRUG" }, { "name": "Midazolam 5 mg (2.5 mL)", "type": "DRUG" }, { "name": "Digoxin 0.25 mg", "type": "DRUG" }, { "name": "Pravastatin 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 20, "start_date": "2020-12-16", "completion_date": "2021-03-10", "has_results": true, "last_update_posted_date": "2024-01-05", "last_synced_at": "2026-09-25T17:04:14.533Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT04425902" }, { "nct_id": "NCT01596907", "title": "Treatment of Low Metabolic Rate Following Bariatric Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Morbid Obesity" ], "interventions": [ { "name": "Ephedrine sulfate with caffeine", "type": "DRUG" }, { "name": "cellulose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Weight Loss Surgery, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 218, "start_date": "2012-05", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-09-24", "last_synced_at": "2026-09-25T17:04:14.533Z", "location_count": 2, "location_summary": "Beaverton, Oregon • Portland, Oregon", "locations": [ { "city": "Beaverton", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01596907" }, { "nct_id": "NCT01710722", "title": "The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "caffeine and ephedrine", "type": "DRUG" }, { "name": "Leptin A", "type": "DRUG" }, { "name": "caffeine, ephedrine, and leptin A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pennington Biomedical Research Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 45, "start_date": "2001-02", "completion_date": "2002-02", "has_results": false, "last_update_posted_date": "2015-12-18", "last_synced_at": "2026-09-25T17:04:14.533Z", "location_count": 1, "location_summary": "Baton Rouge, Louisiana", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01710722" }, { "nct_id": "NCT01842633", "title": "Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Paracetamol and Caffeine", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 365, "start_date": "2013-04-01", "completion_date": "2015-03-31", "has_results": true, "last_update_posted_date": "2017-09-01", "last_synced_at": "2026-09-25T17:04:14.533Z", "location_count": 1, "location_summary": "Waltham, Massachusetts", "locations": [ { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01842633" } ] }